A New Hope for Patients with PH-HFpEF

In the ongoing battle against heart-related conditions, one particular disease remains a formidable challenge: pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF). Affecting a significant number of individuals worldwide, PH-HFpEF currently has no approved treatments, leaving patients and healthcare professionals searching for viable solutions. However, Tenax Therapeutics (Nasdaq: TENX) is now taking a major step forward with its expanded Phase 3 LEVEL program, advancing two registrational studies for TNX-103 (oral levosimendan), a promising new therapy for this devastating condition.

What is TNX-103, and Why Does it Matter?

TNX-103 is an oral formulation of levosimendan, a drug that has been approved in 60 countries (outside the U.S.) for intravenous use in heart failure patients. It works by improving heart and vascular function through multiple mechanisms, including calcium sensitization and potassium ATP channel activation. This dual approach makes it particularly effective in addressing the hemodynamic challenges of PH-HFpEF, a condition characterized by high morbidity and mortality.

Tenax’s expansion of its Phase 3 LEVEL study, alongside the launch of LEVEL-2, marks a pivotal moment in the development of TNX-103 as a potential first-in-class treatment for PH-HFpEF.

FDA Alignment and Study Expansion

On March 5, 2025, Tenax Therapeutics announced that the U.S. Food and Drug Administration (FDA) has reviewed and approved an amendment to its Phase 3 clinical plan, allowing for an increase in enrollment and enhanced statistical power for the LEVEL study. Originally designed to enroll 152 patients, the study will now enroll 230, boosting the statistical power of the study to over 95%—a crucial factor in ensuring reliable and meaningful results.

With more than 50 North American sites already activated, Tenax expects to complete enrollment by the end of 2025 and present topline data by mid-2026. In parallel, the LEVEL-2 study, a global registrational trial, is set to commence this year, further strengthening the clinical development of TNX-103.

Promising Early Results

Initial blinded data from the LEVEL study indicate a strong safety and adherence profile:

• Over 95% of randomized patients have remained on therapy.
• More than 95% of patients completing 12 weeks have chosen to enter the open-label extension (OLE) phase.
• No new safety concerns have been identified, with many patients continuing treatment beyond six months.

Such encouraging trends underscore the potential of TNX-103 as a well-tolerated and effective treatment for PH-HFpEF.

LEVEL-2: A Global Registrational Trial

The LEVEL-2 study will provide even more robust data, assessing the effectiveness of TNX-103 in a larger and more diverse patient population. Unlike LEVEL, which evaluates six-minute walk distance (6MWD) over 12 weeks, LEVEL-2 will assess patients for a full year, offering a comprehensive safety and efficacy profile for regulatory approval in both the U.S. and international markets.

A Potential Paradigm Shift in Cardiopulmonary Care

Dr. Stuart Rich, Chief Medical Officer at Tenax, expressed optimism regarding the progress: “TNX-103 has the potential to meaningfully improve the quality of life of patients with PH-HFpEF, an underdiagnosed disease with significant unmet needs. If the Phase 3 results are positive, these patients may finally have an approved treatment option.”

If successful, TNX-103 could revolutionize the management of PH-HFpEF, providing a much-needed therapeutic option for thousands of patients worldwide.

Investment and Market Outlook

From an investment perspective, Tenax Therapeutics is well-funded following a $100 million financing in August 2024. This financial backing ensures the company can advance its two registrational studies in parallel and sustain operations beyond the expected release of topline LEVEL data in 2026. The potential for TNX-103 to become a first-in-class treatment also makes Tenax an intriguing player in the biopharmaceutical space.

Conclusion

The expansion of the Phase 3 LEVEL program is a critical milestone in the development of TNX-103. With FDA alignment, strong early data, and a well-financed execution plan, Tenax Therapeutics is positioning itself to potentially bring the first approved therapy to patients suffering from PH-HFpEF. As the LEVEL and LEVEL-2 studies progress, the medical community will be watching closely to see if this groundbreaking treatment can redefine the standard of care for a condition that has long been in desperate need of innovation.

For more information, visit www.tenaxthera.com.